Preferred Label : Panobinostat;

MeSH definition : An indole and hydroxamic acid derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used as an antineoplastic agent in combination with BORTEZOMIB and DEXAMETHASONE for the treatment of MULTIPLE MYELOMA.;

MeSH hyponym : NVP-LBH589; NVP LBH589; LBH 589;

MeSH CAS label : 2-Propenamide, N-hydroxy-3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino) methyl)phenyl)-, (2E)-;

Wikipedia link : https://en.wikipedia.org/wiki/Panobinostat;

UNII : 9647FM7Y3Z;

Details


Main resources

You can consult :

An indole and hydroxamic acid derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used as an antineoplastic agent in combination with BORTEZOMIB and DEXAMETHASONE for the treatment of MULTIPLE MYELOMA.

https://ansm.sante.fr/tableau-marr/panobinostat
2024
false
false
false
France
French
risk management
Panobinostat
panobinostat
administration, oral
medication errors
patients guideline
patient compliance

---
https://www.pharmactuel.com/index.php/pharmactuel/article/view/1209
2018
false
false
false
Canada
French
journal article
treatment outcome
disease-free survival
carfilzomib
elotuzumab
daratumumab
antineoplastic agents
antineoplastic agents
ixazomib
recurrence
multiple myeloma
oligopeptides
antibodies, monoclonal, humanized
antibodies, monoclonal
boron compounds
glycine
glycine
indoles
hydroxamic acids
Panobinostat

---
http://www.has-sante.fr/portail/jcms/c_2628641/fr/farydak
2016
false
false
false
France
French
treatment outcome
orphan drug production
panobinostat
antineoplastic agents
antineoplastic combined chemotherapy protocols
dexamethasone
adult
administration, oral
multiple myeloma
Refractory Multiple Myeloma
Recurrent Multiple Myeloma
histone deacetylase inhibitors
aged
Bortezomib
evaluation of the transparency committee
insurance, health, reimbursement
indoles
hydroxamic acids
Panobinostat

---
https://www.ema.europa.eu/medicines/human/EPAR/Farydak
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
orphan drug production
panobinostat
drug approval
europe
drug monitoring
product surveillance, postmarketing
antineoplastic agents
antineoplastic agents
antineoplastic combined chemotherapy protocols
dexamethasone
adult
administration, oral
multiple myeloma
Progression of Multiple Myeloma or Plasma Cell Leukemia
Refractory Multiple Myeloma
Recurrent Multiple Myeloma
histone deacetylase inhibitors
histone deacetylase inhibitors
pregnancy
breast feeding
aged
drug interactions
survival analysis
drug evaluation, preclinical
Bortezomib
indoles
hydroxamic acids
indoles
hydroxamic acids
Panobinostat
Panobinostat

---
Nous contacter.
14/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.